Orthocell is a Regenerative Medicine company developing and commercialising innovative therapies to restore mobility and function. With Remplir and a growing product portfolio, we partner with leading surgeons to improve outcomes for patients worldwide.
We are seeking a Commercial Director, ANZ & APAC to shape and execute Orthocell's growth strategy across Australia, New Zealand, and the broader Asia–Pacific region.
The Role
In this senior leadership position you will:
* Develop and deliver ambitious sales and market expansion strategies across ANZ & APAC.
* Drive successful product launches through alignment of Regulatory, Reimbursement, Marketing, and KOL engagement.
* Negotiate and manage distribution contracts, ensuring alignment with Orthocell's commercial objectives.
* Recruit, lead, and develop a high-performing regional sales and business development team.
* Set and deliver revenue, margin, and market share targets, with full accountability for forecasting and pipeline management.
* Role can be based in Sydney, Melbourne, Brisbane, Perth or Singapore
About You
We're looking for a proven commercial leader with:
* 10+ years in Medical Devices or Biotech, with strong experience across ANZ and APAC markets.
* Deep understanding of distributor networks, channel management, and partnership negotiations.
* Familiarity with Regulatory and Reimbursement pathways across the region.
* A track record of delivering sustained sales growth and exceeding financial targets.
* Strong stakeholder management skills across cultures, with the ability to build trusted relationships with surgeons, partners, and payers.
* Experience in Regenerative Medicine, Orthopaedics, or nerve repair is highly regarded.
Why Join Us?
This is a pivotal opportunity to drive Orthocell's expansion across ANZ & APAC. You'll combine strategic leadership with hands-on execution, shaping commercial outcomes that deliver real impact for patients and healthcare systems.
Application Process
Please submit all applications through the SEEK platform. Applications will be reviewed on Friday 19th September.